Brandes Investment Partners LP Has $152.49 Million Position in Grifols, S.A. (NASDAQ:GRFS)

Brandes Investment Partners LP boosted its holdings in Grifols, S.A. (NASDAQ:GRFS) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,496,093 shares of the biotechnology company’s stock after purchasing an additional 592,096 shares during the quarter. Grifols comprises approximately 1.7% of Brandes Investment Partners LP’s investment portfolio, making the stock its 15th largest holding. Brandes Investment Partners LP owned about 2.98% of Grifols worth $152,491,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of GRFS. Whitebox Advisors LLC lifted its stake in Grifols by 56.2% during the 3rd quarter. Whitebox Advisors LLC now owns 4,221,483 shares of the biotechnology company’s stock valued at $37,487,000 after acquiring an additional 1,519,093 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Grifols by 144.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,002,511 shares of the biotechnology company’s stock valued at $17,782,000 after acquiring an additional 1,181,959 shares in the last quarter. Highland Peak Capital LLC lifted its stake in Grifols by 29.5% during the 4th quarter. Highland Peak Capital LLC now owns 786,210 shares of the biotechnology company’s stock valued at $5,849,000 after acquiring an additional 179,114 shares in the last quarter. Anthracite Investment Company Inc. bought a new position in Grifols during the 3rd quarter valued at $5,457,000. Finally, Barclays PLC lifted its stake in Grifols by 381.2% during the 3rd quarter. Barclays PLC now owns 592,552 shares of the biotechnology company’s stock valued at $5,261,000 after acquiring an additional 469,401 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley assumed coverage on Grifols in a research note on Wednesday, February 12th. They set an “overweight” rating on the stock.

Grifols Trading Up 3.4 %

NASDAQ GRFS opened at $7.98 on Friday. The business’s fifty day moving average is $7.50 and its 200-day moving average is $8.14. Grifols, S.A. has a one year low of $5.79 and a one year high of $9.96. The stock has a market capitalization of $5.49 billion, a price-to-earnings ratio of 6.82 and a beta of 0.35. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.